Alkermes plc - Ordinary Shares — 현금 흐름 (NASDAQ:ALKS)

Financials

영업활동으로 인한 현금 82.84 M101.72 M21.04 M401.35 M439.12 M520.75 M 256.2 M 투자 활동으로 인한 현금 -11.48 M-66.2 M-64.54 M53.36 M-111.31 M295.5 M -1.79 B 재무활동으로 인한 현금 -2.17 M29.07 M-1.57 M-289.71 M-494.14 M12.38 M 1.49 B 잉여 현금 흐름 82.84 M101.72 M21.04 M401.35 M439.12 M480.33 M 221.8 M

Alkermes plc - Ordinary Shares

Alkermes plc is a fully-integrated biopharmaceutical company that focuses on developing medicines for psychiatric and neurological disorders. The company was founded in 1987 by Michael Wall. In September 2011 Alkermes, Inc. merged with Elan Drug Technologies, the former drug formulation and manufacturing division of Élan Corporation, plc. The company is headquartered in Dublin, and has an R&D center in Waltham, Massachusetts, and a manufacturing facility in Wilmington, Ohio.

ALKS

Financials

Alkermes plc - Ordinary Shares

뉴스

Alkermes Analysts Increase Their Forecasts Following Strong Q1 Results - Alkermes (NASDAQ:ALKS)

Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises

Alkermes: A Sleep Medicine Platform Hidden Inside A Mature CNS Company (ALKS)

Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Alkermes (ALKS) Reports Q1 Loss, Beats Revenue Estimates

Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth

TEVA Q1 Earnings Top Estimates, Branded Drugs Drive Revenues, Stock Up

Bristol Myers Squibb (BMY) Tops Q1 Earnings and Revenue Estimates

Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline

Wall Street Analysts Believe Alkermes (ALKS) Could Rally 29.14%: Here's is How to Trade